Seres Q4 net loss from continuing ops $15.7M; cash extends into Q1 2026; SER-155 advances

Seres Therapeutics, Inc.

Net loss from continuing ops: FY2024 $125.8M vs $190.1M in 2023; Q4 $15.7M vs $34.7M.
R&D expenses fell to $64.6M (FY2024) from $117.6M; focus on lead program SER-155.
Cash $30.8M at Dec 31; plus $50M received Jan 2025, expects funding into Q1 2026.
SER-155: FDA supports BSI reduction at day 30 as Phase 2 endpoint; draft protocol in Q2 2025.
Expecting $25M Nestlé installment in July 2025; VOWST sale yields up to $275M in milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.